Consumer Defensive
Goldenwell Biotech, Inc.(GWLL)
Live Price
Offline$0.52
+0.00% today
1Y Change
+160.00%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $100.00M
- Revenue Growth
- -94.1%
- EPS Growth
- -8.3%
- Dividend Yield
- 0.0%
Coverage: 253 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Goldenwell Biotech, Inc. (GWLL) is a Consumer Defensive stock with a market cap of $100.00M and listed on OTC. The stock last traded around $0.52 and up 160.0% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of -94.1%, EPS growth of -8.3%, a dividend yield of 0.0%. What stands out right now is revenue -94.1%, EPS -8.3%, free cash flow -7.3% with operating margin -96.9% and ROIC -33.4%. Valuation already assumes a fairly strong business story at price/sales 1588.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GWLL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-94.1% vs +1.7% peer median
Operating Margin
Below sector median
-96.9% vs +6.6% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -94.1% and EPS is at -8.3%, with operating margin around -96.9%.
Benchmark Edge
GWLL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GWLL
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GWLL Max Drawdown
-92.71%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GWLL and SPY.
Company Overview
Goldenwell Biotech, Inc.
Other OTC
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. The company is developing five products, including JI MAIβbovine cardiac vascular active peptide; cartilage peptide, a type II collagen peptide; and Double Proline AG Β 3D active collagen peptide, as well as DNA repair tablets and sugar master tablets. The company was incorporated in 2019 and is based in Twinsburg, Ohio.
- Leadership
- Shuang Liu
- IPO Date
- Sep 30, 2022
- Employees
- 3
- Street Address
- 2071 Midway Drive
- Mailing
- Hudson, OH, 44087
- Region
- Hudson, OH, US
- Reporting Currency
- USD
- Investor Line
- 440 666 7999
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 1588.0
- Price/Book
- β
Growth
- Revenue
- -94.1%
- EPS
- -8.3%
- Free Cash Flow
- -7.3%
Profitability
- Gross Margin
- 100.1%
- Operating Margin
- -96.9%
- Net Margin
- -120.5%
- ROE
- 96.8%
- ROIC
- -33.4%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 5.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.